secukinumab vs vunakizumab

NCT01392326 · Phase 3 · completed

In this large (n=606), randomized, quadruple-blind, placebo-controlled Phase 3 trial in active psoriatic arthritis, significantly more patients achieved an ACR20 response at week 24 on secukinumab 75 mg (50.5%) or 150 mg (50.0%) than on placebo (17.3%), a statistically significant difference for both doses (p<0.0001).

NCT05055934 · Phase 2 · completed

The study was randomized, quadruple-blind, placebo-controlled, and included 112 participants, using the clinical ACR20 improvement measure as its primary endpoint. Because the registry does not report whether the primary endpoint was met, the trial provides well-designed but currently incomplete evidence.

NCT01358578 · Phase 3 · completed

This was a large, randomized, quadruple-blind trial with both placebo and active etanercept comparator groups, enrolling 1,306 participants. The clinical primary endpoints at week 12 were met in the favorable direction based on the reported counts: PASI 75 and IGA 0/1 responses were achieved by large majorities of secukinumab-treated participants compared with very few placebo-treated participants, although formal statistical analyses are not posted in the registry.

NCT04839016 · Phase 3 · status unknown

This randomised, double-blind, placebo-controlled trial in 660 patients with moderate-to-severe plaque psoriasis reported PASI 90 in 76.8% of patients on vunakizumab against 0.9% on placebo at week 12, with sPGA 0/1 in 71.8% against 0.4%, both standard measures of skin clearance.